Patent search ap:("TAKEDA PHARMACEUTICAL COMPANY LIMITED") AND inv:"Masaki OGINO" Page 1

1.

发明申请
HETEROCYCLIC COMPOUND AND USE THEREOF 审中-公开

公开(公告)号：US20190040010A1

公开(公告)日：2019-02-07

申请号：US16052967

申请日：2018-08-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita , Satoshi MIKAMI , Yuhei MIYANOHANA , Tatsuki KOIKE , Masaki DAINI , Norio OHYABU , Masaki OGINO , Kohei TAKEUCHI , Yoshiteru ITO , Norihito TOKUNAGA , Takahiro SUGIMOTO , Tohru MIYAZAKI , Tsuneo ODA , Yasutaka HOASHI , Yasushi HATTORI , Keisuke IMAMURA

IPC: C07D211/56 , C07D401/10 , C07D401/06 , C07D207/14 , C07D405/10 , C07D417/06 , C07D405/12 , C07D413/06 , C07D401/14 , C07D205/04 , C07D403/06 , C07D417/14 , A61P25/00

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

2.

发明申请
HETEROCYCLIC COMPOUND 审中-公开

公开(公告)号：US20170362223A1

公开(公告)日：2017-12-21

申请号：US15538297

申请日：2015-12-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji KIMURA , Yuhei MIYANOHANA , Masaki OGINO , Yuta TANAKA , Makoto FUSHIMI , Tomohiro OKAWA , Yuki HANYA , Tatsuki KOIKE

IPC: C07D471/04

CPC classification number: C07D471/04 , A61P25/00 , A61P29/00 , C07D487/04

Abstract: Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.

3.

发明申请
NITROGEN-CONTAINING HETEROCYCLIC COMPOUND 审中-公开

公开(公告)号：US20170121308A1

公开(公告)日：2017-05-04

申请号：US15318552

申请日：2015-06-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masaki OGINO , Eiji KIMURA , Shinkichi SUZUKI , Tomoko ASHIZAWA , Toshihiro IMAEDA , Ikuo FUJIMORI , Ryosuke ARAI

IPC: C07D401/10 , C07D213/81 , C07D405/14

CPC classification number: C07D401/10 , A61K31/44 , A61K31/4439 , A61K31/444 , C07D213/81 , C07D401/14 , C07D405/12 , C07D405/14

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.

4.

发明申请
HETEROCYCLIC COMPOUND 有权
Title translation: 杂环化合物

公开(公告)号：US20160376244A1

公开(公告)日：2016-12-29

申请号：US15190642

申请日：2016-06-23

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Jinichi YONEMORI , Takuto KOJIMA

IPC: C07D265/22 , C07D413/06 , C07D491/107 , C07D413/04 , C07F7/02 , C07D471/04 , C07D413/14 , C07D413/10

CPC classification number: C07D413/14 , A61P25/28 , C07B2200/07 , C07D265/22 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

Abstract translation: 其中每个符号如所附的说明中所定义。

5.

发明申请
HETEROCYCLIC COMPOUND 审中-公开
Title translation: 杂环化合物

公开(公告)号：US20150299188A1

公开(公告)日：2015-10-22

申请号：US14423310

申请日：2013-08-23

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masaki OGINO , Zenichi IKEDA , Jun FUJIMOTO , Yusuke OHBA , Naoki ISHII , Takuya FUJIMOTO , Tsuneo ODA , Naohiro TAYA , Toshiro YAMASHITA , Nobuyuki MATSUNAGA

IPC: C07D471/04

CPC classification number: C07D471/04 , A61K9/2018 , A61K9/4858 , C07D239/80 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D409/12 , C07D413/04 , C07D417/12 , C07D487/04 , C07D513/04 , C07D519/00

Abstract: Provided is a compound having a superior FLAP inhibitory action and useful as a prophylactic or therapeutic agent for arteriosclerosis and the like, and a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present DESCRIPTION, or a salt thereof.

Abstract translation: 提供具有优异的FLAP抑制作用并可用作动脉硬化等的预防或治疗剂及其盐的化合物。本发明涉及由下式表示的化合物，其中各符号如本说明书所定义，或其盐。

6.

发明申请
HETEROCYCLIC COMPOUND AND USE THEREOF 审中-公开

公开(公告)号：US20200207734A1

公开(公告)日：2020-07-02

申请号：US16633960

申请日：2018-08-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi KAJITA , Satoshi MIKAMI , Yuhei MIYANOHANA , Tatsuki KOIKE , Masaki DAINI , Norio OYABU , Masaki OGINO , Kohei TAKEUCHI , Yoshiteru ITO , Norihito TOKUNAGA , Takahiro SUGIMOTO , Tohru MIYAZAKI , Tsuneo ODA , Yasutaka HOASHI , Yasushi HATTORI , Keisuke IMAMURA

IPC: C07D401/06 , C07D211/56 , C07D401/10 , C07D405/10 , C07D207/14 , C07D417/06 , C07D405/12 , C07D409/10 , C07D413/06 , C07D401/14 , C07D205/04 , A61P25/26

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

7.

发明申请
AROMATIC RING COMPOUND 审中-公开

公开(公告)号：US20190083467A1

公开(公告)日：2019-03-21

申请号：US16083295

申请日：2017-03-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masaki OGINO , Eiji KIMURA , Shinkichi SUZUKI , Kouji FUJI , Tomohiro OHASHI , Makoto FUSHIMI , Kei MASUDA , Tatsuki KOIKE , Takeshi WAKABAYASHI , Jinichi YONEMORI , Masami YAMADA

IPC: A61K31/4192 , A61K31/4155 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/28

Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.

8.

发明申请
HETEROCYCLIC COMPOUND 审中-公开

公开(公告)号：US20180303841A1

公开(公告)日：2018-10-25

申请号：US15769295

申请日：2016-10-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Takuto KOJIMA , Jinichi YONEMORI

IPC: A61K31/53 , A61P25/04 , A61P25/16 , A61P25/18 , A61P25/28

CPC classification number: A61K31/53 , A61K31/517 , A61P25/04 , A61P25/16 , A61P25/18 , A61P25/28 , C07D239/88 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/10 , C07D405/14

Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.